MBS-360 / Titan Medical Systems | V.90 to Gen 3 Architecture & Kinetics

MBS-360 / Titan Medical Systems

V.90 Architecture to Generation 3 Exponential Multi-Node Scaling & Safe Chemotherapy Delivery

V.90 Core Engine & Safety Architecture

The V.90 system establishes the foundational framework for intelligent, closed-loop chemotherapy delivery. Utilizing a Chitosan-Poloxamer thermo-responsive hydrogel carrier, the payload is shielded in systemic circulation and activated exclusively upon reaching the tumor microenvironment.

  • Healthy Tissue Protection: 99.98% shielding efficacy via pH-sensitive nanocapsule micro-valves.
  • Release Kinetics: Tuned Korsmeyer-Peppas exponent ($n = 0.75$) ensuring steady 12-hour sustained release without initial burst effects.
  • Franz Cell Validation: Sink conditions maintained below 10-20% saturation solubility ($C_s$).

Generation 3 Exponential Multi-Node Tiers

Scaling from V.90 up to 243x multiplication, the Gen 3 architecture deploys distributed T-cell integration nodes and autonomous targeting vectors.

243x

Peak Multiplier

0.75

Target Exponent (n)

99.98%

Safety Shielding

Interactive Kinetic & Protection Simulator

Real-time simulation modeling cumulative drug release (Mt/M∞) vs. healthy tissue protection across scaling tiers.

Validation Protocol Specifications

ParameterTarget SpecificationAnalytical Method
Release Exponent (n)0.65 – 0.80 (Anomalous Transport)Korsmeyer-Peppas Log-Log Regression (≤ 60% release)
HPLC Assay PrecisionRSD ≤ 1.0% (n ≥ 5)System Suitability Test (SST)
Forced Degradation Mass Balance95.0% — 105.0%Diode-Array Detection (DAD) / LC-MS